Russell-Smith TA[Author] - Search Results

Year	Number of Results
2020	1
2021	2
2022	3
2023	1
2024	0

1

Efficacy of non-intensive therapies approved for relapsed/refractory acute myeloid leukemia: a systematic literature review.

Russell-Smith TA, Gurskyte L, Muresan B, Mamolo CM, Gezin A, Cappelleri JC, Heeg B. Russell-Smith TA, et al. Future Oncol. 2022 May;18(16):2029-2039. doi: 10.2217/fon-2021-1355. Epub 2022 Feb 24. Future Oncol. 2022. PMID: 35196866 Free article. Review.

2

The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price.

Mladsi D, Barnett CL, Mader G, Russell-Smith TA, Unuigbe A, Bell T. Mladsi D, et al. Among authors: russell smith ta. Value Health. 2023 Mar;26(3):384-391. doi: 10.1016/j.jval.2023.01.004. Epub 2023 Jan 24. Value Health. 2023. PMID: 36706950 Free article.

3

Systematic review and pooled analysis of survival outcomes in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia who have undergone haematopoietic stem cell transplant.

Russell-Smith TA, Chadda S, LeReun C, Bajko P, Doogan E. Russell-Smith TA, et al. Eur Rev Med Pharmacol Sci. 2022 Feb;26(3):975-995. doi: 10.26355/eurrev_202202_28007. Eur Rev Med Pharmacol Sci. 2022. PMID: 35179764 Free article.

4

Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden.

van Oostrum I, Russell-Smith TA, Jakobsson M, Torup Østby J, Heeg B. van Oostrum I, et al. Among authors: russell smith ta. Pharmacoecon Open. 2022 Jan;6(1):47-62. doi: 10.1007/s41669-021-00287-2. Epub 2021 Jul 26. Pharmacoecon Open. 2022. PMID: 34309818 Free PMC article.

5

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK.

Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Russell-Smith TA, et al. Pharmacoecon Open. 2021 Dec;5(4):677-691. doi: 10.1007/s41669-021-00278-3. Epub 2021 Jun 28. Pharmacoecon Open. 2021. PMID: 34181204 Free PMC article.

6

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.

Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ; BYOND Study Investigators. Hochhaus A, et al. Among authors: russell smith ta. Leukemia. 2020 Aug;34(8):2125-2137. doi: 10.1038/s41375-020-0915-9. Epub 2020 Jun 22. Leukemia. 2020. PMID: 32572189 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

6 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year